The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2025 | How off-the-shelf cellular therapies may change the treatment landscape in myeloma
In this interview, Karlo Perica, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the potential of off-the-shelf cellular therapy products to revolutionize the treatment landscape of multiple myeloma (MM) by combining the efficacy of autologous CAR T-cell therapy with the ease of administration of bispecific antibodies. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
At our center, the vein-to-vein, or even more importantly, the brain-to-vein time, as we call it, the idea of the first day you decide you’re going to give CAR T-cell therapy to the time the patient gets it, can be months. And that’s not just due to the manufacturing time of autologous CAR T-cell cells. It’s due to the complexity of scheduling patient collection, apheresis, obtaining insurance approval, making sure there’s bed availability, all the factors that are necessary for this complex therapy to work...
At our center, the vein-to-vein, or even more importantly, the brain-to-vein time, as we call it, the idea of the first day you decide you’re going to give CAR T-cell therapy to the time the patient gets it, can be months. And that’s not just due to the manufacturing time of autologous CAR T-cell cells. It’s due to the complexity of scheduling patient collection, apheresis, obtaining insurance approval, making sure there’s bed availability, all the factors that are necessary for this complex therapy to work. Off-the-shelf cell therapies could definitely bring a big change to that. Now, we do have to keep in mind that there is a very effective class of off-the-shelf immunotherapies that already exists – bispecifics. And so you will see at many centers different practice patterns based off the perceived relative efficacy of CAR T-cells, particularly cilta-cel, versus the ease of administration of an immediately available off-the-shelf bispecific. The hope of these off-the-shelf cell therapies is that you could get both. And of course, that hasn’t been demonstrated yet. If it were to be demonstrated, it would definitely be a game changer for the field.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
